Urine immunofixation electrophoresis remains important and is complementary to serum free light chain

Clinical Chemistry and Laboratory Medicine

Volumn 49, Issue 11, 2011, Pages 1801-1804

  Levinson, Stanley S ^a,b  

^a VETERANS AFFAIRS MEDICAL CENTER   (United States)

^b University of Louisville School of Medicine   (United States)

Author keywords

Analytical sensitivity; Immunofixation electrophoresis; Methodological imperfection; Serum free light chain assay; Urine protein electrophoresis

Indexed keywords

BENCE JONES PROTEIN;

ASSAY; ELECTROPHORESIS; HUMAN; IMMUNOFIXATION ELECTROPHORESIS; LIGHT CHAIN; MONOCLONAL IMMUNOGLOBULINEMIA; PRIORITY JOURNAL; REVIEW; SENSITIVITY AND SPECIFICITY; SERUM FREE LIGHT CHAIN ASSAY; URINALYSIS;

BENCE JONES PROTEIN; HUMANS; IMMUNOASSAY; IMMUNOELECTROPHORESIS; IMMUNOGLOBULIN KAPPA-CHAINS; IMMUNOGLOBULIN LAMBDA-CHAINS; MULTIPLE MYELOMA; PARAPROTEINEMIAS; REFERENCE VALUES; SENSITIVITY AND SPECIFICITY; SERUM; URINALYSIS;

EID: 80755130087     PISSN: 14346621     EISSN: 14374331     Source Type: Journal    
DOI: 10.1515/CCLM.2011.641     Document Type: Review

References (32)

1. Holding S, Spradbery D, Hoole R, Wilmot R, Shields ML, Levoguer AM, et al. Use of serum free light chain analysis and urine protein electrophoresis for detection of monoclonal gammopathies. Clin Chem Lab Med 2011;49:83-8.
2. Palladini G, Russo P, Bosoni T, Verga L, Sarais G, Lavatelli F, et al. Identification of amyloidogenic light chains requires the combination of serum-free light chain assay with immunofixation of serum and urine. Clin Chem 2009;55:499-504.
3. Shaheen SP, Levinson SS. Serum free light chain analysis may miss monoclonal light chains that urine immunofixation electrophoreses would detect. Clin Chim Acta 2009;406:162-6.
4. Dispenzieri A, Kyle R, Merlini G, Miguel JS, Ludwig H, Hajek R, et al. International Myeloma Working Group guidelines for serum-free light chain analysis in multiple myeloma and related disorders. Leukemia 2009;23:215-24.
5. Merlini G. Serum-free light chain analysis: works in progress. Clin Chem Lab Med 2009;47:1021-2.
6. Keren DF, Alexanian R, Goeken JA, Gorevic PD, Kyle RA, Tomar RH. Guidelines for clinical and laboratory evaluation of patients with monoclonal gammopathies. Arch Pathol Lab Med 1999;123:106-7. (Pubitemid 29093593)
7. Levinson SS, Elin RJ, Yam L. Light chain proteinuria and lysozymuria in a patient with acute monocytic leukemia. Clin Chem 2002;48:1131-2. (Pubitemid 34680921)
8. Kaplan IV, Levinson SS. Misleading urinary protein pattern in a patient with hypogammaglobulinemia: effects of mechanical concentration of urine. Clin Chem 1999;45:417-9. (Pubitemid 29114182)
9. Roden AC, Lockington KS, Tostrud LJ, Katzmann JA. Urine protein electrophoresis and immunoelectrophoresis using unconcentrated or minimally concentrated urine samples. Am J Clin Pathol 2008;130:141-5.
10. Levinson SS, Keren DF. Free light chains of immunoglobulins: clinical laboratory analysis. Clin Chem 1994;40:1869-78. (Pubitemid 24332687)
11. Bradwell AR, Carr-Smith HD, Mead GP, Harvey TC, Drayson MT. Serum test for assessment of patients with Bence Jones myeloma. Lancet 2003;361:489-91. (Pubitemid 36173716)
12. Levinson SS. Polyclonal free light chain of Ig may interfere with interpretation of monoclonal free light chain kappa/lambda ratio. Ann Clin Lab Sci 2010;40:348-53.
13. Marshall G, Tate J, Mollee P. Borderline high serum free light chain kappa/lambda ratios are seen not only in dialysis patients but also in non-dialysis-dependent renal impairment and inflammatory states. Am J Clin Pathol 2009;132:309.
14. Katzmann JA, Kyle RA, Benson J, Larson DR, Snyder MR, Lust JA, et al. Screening panels for detection of monoclonal gammopathies. Clin Chem 2009;55:1517-22.
15. Harrison HH. The "ladder light chain" or "pseudo- oligoclonal" pattern in urinary immunofixation electrophoresis (IFE) studies: a distinctive IFE pattern and an explanatory hypothesis relating it to free polyclonal light chains. Clin Chem 1991;37: 1559-64. (Pubitemid 21905217)
16. MacNamara EM, Aguzzi F, Petrini C, Higginson J, Gasparro C, Bergami MR, et al. Restricted electrophoretic heterogeneity of immunoglobulin light chains in urine: a cause for confusion with Bence Jones protein. Clin Chem 1991;37:1570-4. (Pubitemid 21905219)
17. Briand PY, Decaux O, Caillon H, Grosbois B, Le Treut A, Guenet L. Analytical performance of the serum free light chain assay. Clin Chem Lab Med 2010;48:73-9.
18. de Kat Angelino CM, Raymakers R, Teunesen MA, Jacobs JF, Klasen IS. Overestimation of serum kappa free light chain concentration by immunonephelometry. Clin Chem 2010;56:1188-90.
19. Levinson SS. Regarding the overestimation of serum {kappa} free light chains. Clin Chem 2011;57:775-7.
20. Tate J, Mollee P, Johnson R. Monoclonal gammopathies - clinical and laboratory issues. Clin Biochem Rev 2009;30:89-91.
21. Tate JR, Mollee P, Dimeski G, Carter AC, Gill D. Analytical performance of serum free light-chain assay during monitoring of patients with monoclonal light-chain diseases. Clin Chim Acta 2007;376:30-6. (Pubitemid 44880976)
22. Katzmann JA, Clark RJ, Abraham RS, Bryant S, Lymp JF, Bradwell AR, et al. Serum reference intervals and diagnostic ranges for free kappa and free lambda immunoglobulin light chains: relative sensitivity for detection of monoclonal light chains. Clin Chem 2002;48:1437-44. (Pubitemid 34925779)
23. Hutchison CA, Harding S, Hewins P, Mead GP, Townsend J, Bradwell AR, et al. Quantitative assessment of serum and urinary polyclonal free light chains in patients with chronic kidney disease. Clin J Am Soc Nephrol 2008;3:1684-90.
24. Falk RH, Comenzo RL, Skinner M. The systemic amyloidoses. N Engl J Med 1997;337:898-909. (Pubitemid 27408573)
25. Durie BG, Harousseau JL, Miguel JS, Blade J, Barlogie B, Anderson K, et al. International uniform response criteria for multiple myeloma. Leukemia 2006;20:1467-73. (Pubitemid 44264086)
26. Mollee P. Current trends in the diagnosis, therapy and monitoring of the monoclonal gammopathies. Clin Biochem Rev 2009;30:93-103.
27. Katzmann JA. Screening panels for monoclonal gammopathies: time to change. Clin Biochem Rev 2009;30:105-11.
28. Singhal S, Vickrey E, Krishnamurthy J, Singh V, Allen S, Mehta J. The relationship between the serum free light chain assay and serum immunofixation electrophoresis, and the definition of concordant and discordant free light chain ratios. Blood 2009;114:38-9.
29. Uljon SN, Richardson PG, Schur PH, Anderson KC, Tanasijevic MJ, Lindeman NI. Serial serum free light chain measurements do not detect changes in disease status earlier than electrophoretic M-spike measurements in patients with intact immunoglobulin myeloma. Clin Chim Acta 2011;412:562-8.
30. Lachmann HJ, Booth DR, Booth SE, Bybee A, Gilbertson JA, Gillmore JD, et al. Misdiagnosis of hereditary amyloidosis as AL (primary) amyloidosis. N Engl J Med 2002;346:1786-91. (Pubitemid 34586914)
31. Tate J, Bazeley S, Sykes S, Mollee P. Quantitative serum free light chain assay-analytical issues. Clin Biochem Rev 2009;30: 131-40.
32. Levinson SS. Hook effect with lambda free light chain in serum free light chain assay. Clin Chim Acta 2010;411:1834-6.